Coformulated vibostolimab/pembrolizumab clinical trials

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

This study looks at new drug combinations for advanced bladder cancer. Doctors want to see if adding different medicines to pembrolizumab and enfortumab vedotin (EV) works better and is safe. The goal is to find new, effective treatments for patients.